The effect of different antibiotic protocols for dental implant surgery on peri-implant tissue health and on oral microbiome and resistome

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510391-31-00

Enrollment

Registered

2024-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy patients

Brief summary

Mean bone loss

Detailed description

- Incidence of biological and technical complications - Implant survival rate (CSR) - Antibiotic sensitivity 1 week before and 2-6 months after implant insertion - Peri-implant myco-, microbiome and resistome 1 week before and 2-6 months after implant insertion - Salivary miRNomics 1 week before and 2 months after implant insertion - Adverse reactions - Development of a 3D bone model (sub-study) - Plaque index (PI), Bleeding on probing (BOP) and probing depth (PPD) a at 3, 6 and 12 months

Interventions

DRUGZIMOX 1 g compresse

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Mean bone loss	—

Secondary

Measure	Time frame
- Incidence of biological and technical complications - Implant survival rate (CSR) - Antibiotic sensitivity 1 week before and 2-6 months after implant insertion - Peri-implant myco-, microbiome and resistome 1 week before and 2-6 months after implant insertion - Salivary miRNomics 1 week before and 2 months after implant insertion - Adverse reactions - Development of a 3D bone model (sub-study) - Plaque index (PI), Bleeding on probing (BOP) and probing depth (PPD) a at 3, 6 and 12 months	—

Measure

Time frame

—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026